<DOC>
	<DOC>NCT02002221</DOC>
	<brief_summary>The purpose of this study was to assess the efficacy and safety of vildagliptin 50 mg bid add-on therapy to improve overall glycemic control in patients with T2DM inadequately controlled by insulin, with or without concomitant metformin treatment. It was agreed with PMDA to conduct a postmarketing clinical trial to further collect the efficacy and safety data of vildagliptin especially in Japanese patients when it iwas used on top of insulin.</brief_summary>
	<brief_title>Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Confirmed diagnosis of T2DM by standard criteria. HbA1c ≥ 7.0 to ≤ 10% at Visit 1. Age: ≥ 20 to &lt; 75 years old at Visit 1. BMI ≥ 20 to ≤ 35 kg/m2 at Visit 1. FPG ≥ 270 mg/dL (≥15 mmol/L) at Visit 1. Type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes. Significant heart diseases Hepatic disorder Other protocol defined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Diabetes Mellitus (DM) ,</keyword>
	<keyword>diabetes,</keyword>
	<keyword>noninsulin-dependent diabetes mellitus (NIDDM),</keyword>
	<keyword>adult-onset diabetes,</keyword>
	<keyword>high blood sugar,</keyword>
	<keyword>T2DM</keyword>
</DOC>